Raymond James analyst Lawrence Keusch maintained a Buy rating on Masimo (NASDAQ:MASI) Corp on Tuesday, setting a price target of $250, which is approximately 8.34% above the present share price of $230.76.
Keusch expects Masimo Corp to post earnings per share (EPS) of $1.02 for the third quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Masimo, with an average price target of $254.
The analysts price targets range from a high of $260 to a low of $250.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $300.95 million and a net profit of $62.25 million. The company's market cap is $12.68 billion.
According to TipRanks.com, Raymond James analyst Lawrence Keusch is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.2% and a 57.66% success rate.
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.